Literature DB >> 22605536

Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm?

Mary-Ann Fitzcharles1, Jason McDougall, Peter A Ste-Marie, Ivan Padjen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22605536     DOI: 10.1002/art.34522

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


× No keyword cloud information.
  5 in total

1.  Critical role of extracellular vesicles in modulating the cellular effects of cytokines.

Authors:  Géza Tamás Szabó; Bettina Tarr; Krisztina Pálóczi; Katalin Éder; Eszter Lajkó; Ágnes Kittel; Sára Tóth; Bence György; Mária Pásztói; Andrea Németh; Xabier Osteikoetxea; Éva Pállinger; András Falus; Katalin Szabó-Taylor; Edit Irén Buzás
Journal:  Cell Mol Life Sci       Date:  2014-04-06       Impact factor: 9.261

Review 2.  Cannabinoids in the Management of Musculoskeletal or Rheumatic Diseases.

Authors:  Mary-Ann Fitzcharles; Winfried Häuser
Journal:  Curr Rheumatol Rep       Date:  2016-12       Impact factor: 4.592

Review 3.  The endocannabinoid system in pain and inflammation: Its relevance to rheumatic disease.

Authors:  Nicola Barrie; Nicholas Manolios
Journal:  Eur J Rheumatol       Date:  2017-09-01

Review 4.  Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges.

Authors:  Attila Oláh; Zoltán Szekanecz; Tamás Bíró
Journal:  Front Immunol       Date:  2017-11-10       Impact factor: 7.561

5.  Rheumatologists lack confidence in their knowledge of cannabinoids pertaining to the management of rheumatic complaints.

Authors:  Mary-Ann Fitzcharles; Peter A Ste-Marie; Daniel J Clauw; Shahin Jamal; Jacob Karsh; Sharon LeClercq; Jason J McDougall; Yoram Shir; Kam Shojania; Zach Walsh
Journal:  BMC Musculoskelet Disord       Date:  2014-07-30       Impact factor: 2.362

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.